Treatment of tumor slices prepared from AR-positive (LuCaP 147 CR) tumors with various pharmacological agents, including high doses (5 μM) of docetaxel and enzalutamide, showed no effect (101% of control for docetaxel and 84% of control for enzalutamide) on tissue viability, while treatment with a low dose (500 nM) of staurosporine (a multi-kinase inhibitor) decreased (>2-fold) overall tissue viability (Figure 5b). The gene discussed is AR; the disease is neoplasm.